Form 4: Tarsus Pharmaceuticals Chief Commercial Officer Sells Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, Inc., sold 17,500 shares of common stock for approximately $43.76 per share as part of a pre-scheduled Rule 10b5-1 trading plan.
Summary
- Aziz Mottiwala, the Chief Commercial Officer of Tarsus Pharmaceuticals, Inc. (TARS), reported the sale of 17,500 shares of the company's common stock.
- The transaction occurred on June 9, 2025, at a weighted average price of $43.76 per share.
- The shares were sold in multiple transactions with prices ranging from $43.42 to $44.55.
- Following this transaction, Mr. Mottiwala beneficially owns 47,557 shares of Tarsus Pharmaceuticals common stock.
- The sale was executed automatically pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Mottiwala on March 10, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-arranged Rule 10b5-1 plan mitigates any negative inference, as it indicates a planned financial management decision rather than a reaction to adverse company news.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to recent company performance or news.
Negatives
- An insider sale, even if pre-planned, reduces the direct ownership stake of a key executive in the company.
Future Outlook
NA
Management Comments
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2025.
- The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.
Industry Context
This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends within the pharmaceutical or biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Attorney-in-Fact | Aziz Mottiwala granted a Power of Attorney to several individuals, including Bobak Azamian, Jeffrey Farrow, Bryan Wahl, Scott Sieckert, Nicole Golan, Shannon Callan, Jacob Brouwer, and Kristine Mengoli, to execute and file SEC Forms 3, 4, and 5 on his behalf. This ensures compliance with Section 16 of the Securities Exchange Act of 1934. | 03/27/2025 | Streamlines the process for insider reporting compliance, ensuring timely and accurate filings by authorized representatives. |
Stakeholder Impact
- Shareholders: The sale of shares by a Chief Commercial Officer, even under a 10b5-1 plan, might be noted by investors, but is generally not considered a significant indicator of company performance or future prospects due to its pre-planned nature.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date Rule 10b5-1 trading plan was adopted by Aziz Mottiwala. |
| 03/27/2025 | Date Power of Attorney was executed by Aziz Mottiwala. |
| 06/09/2025 | Date of reported stock transaction (sale of shares). |
| 06/11/2025 | Date Form 4 was signed. |
Keywords
Tarsus Pharmaceuticals, TARS, SEC Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Chief Commercial Officer, Aziz Mottiwala, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.